SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-039578
Filing Date
2024-10-04
Accepted
2024-10-04 17:27:26
Documents
17
Period of Report
2024-09-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43067
2 ex16-1.htm EX-16.1 4251
3 ex16-1_001.jpg GRAPHIC 84366
4 ex16-1_002.jpg GRAPHIC 9071
5 ex16-1_003.jpg GRAPHIC 45991
  Complete submission text file 0001493152-24-039578.txt   417223

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE prph-20240930.xsd EX-101.SCH 3027
7 XBRL LABEL FILE prph-20240930_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE prph-20240930_pre.xml EX-101.PRE 24173
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3686
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 241355742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)